N-(4-Dimethylamino-butyl)-phthalimid | 92292-92-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: N-(4-Dimethylamino-butyl)-phthalimid
• 英文别名: N-(4-dimethylamino-butyl)-phtalimide；2-[4-(dimethylamino)butyl]isoindole-1,3-dione
• CAS: 92292-92-7
• 化学式: C₁₄H₁₈N₂O₂
• 分子量: 246.309
• InChiKey: CDLMLECQAFYAKW-UHFFFAOYSA-N

物化性质

• 沸点：
  218-220 °C(Press: 33 Torr)
• 密度：
  1.153±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  40.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(4-Dimethylamino-butyl)-phthalimid 在 二氮烯 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 4-二甲基氨基丁胺
  参考文献：
  名称：

  一类新的组胺H（3）-受体拮抗剂：7,8,9,10-四氢-6H-环庚[b]喹啉的合成与构效关系。

  摘要：

  描述了人类H（3）受体的新型环庚喹啉拮抗剂的合成和生物学评估。研究了两个在11位带有氨基取代基或炔烃连接基的化合物。描述了氨基取代基的修饰，链长的优化和构象约束的影响。发现了几种对H（3）受体具有高亲和力和选择性的化合物。

  DOI：

  10.1016/s0960-894x(03)00356-1
• 作为产物：
  描述：

  邻苯二甲酸亚胺 在 苄基三乙基氯化铵 、 potassium carbonate 、 三乙胺 作用下， 以 甲醇 、 丙酮 为溶剂， 反应 24.0h， 生成 N-(4-Dimethylamino-butyl)-phthalimid
  参考文献：
  名称：

  新型多靶标定向三嗪并吲哚衍生物作为抗阿尔茨海默病药物。

  摘要：

  阿尔茨海默氏病（AD）的多面性要求使用多靶标配体（MTDL）进行治疗以应对关键的病理畸变。设计并合成了一系列新颖的三嗪并吲哚衍生物。体外研究表明，所有化合物均显示出中等至良好的抗胆碱酯酶活性。活性最高的化合物23e对AChE的IC50值为0.56±0.02μM，对BuChE的IC50值为1.17±0.09μM。这些衍生物还具有强大的抗氧化活性。为了理解化合物23e的合理结合模式，进行了分子对接研究和分子动力学模拟研究，结果表明23e在AChE和BuChE的活性位点之间发生了显着的相互作用。化合物23e成功地减轻了SH-SY5Y细胞中H2O2诱导的氧化应激，并以浓度依赖的方式对SH-SY5Y细胞表现出优异的抗H2O2神经保护活性以及Aβ诱导的毒性。此外，在细胞毒性试验中，它对神经元SH-SY5Y细胞未显示任何明显的毒性。化合物23e在高达2000 mg / kg的剂量下未在大鼠中表现出任何急

  DOI：

  10.1021/acschemneuro.9b00226

文献信息

• Cytotoxic Glycosylated Fatty Acid Amides from a <i>Stelletta</i> sp. Marine Sponge
  作者：Victoria Peddie、Kentaro Takada、Shujiro Okuda、Yuji Ise、Yasuhiro Morii、Nobuhiro Yamawaki、Tomohiro Takatani、Osamu Arakawa、Shigeru Okada、Shigeki Matsunaga

  DOI：10.1021/acs.jnatprod.5b00795

  日期：2015.11.25

  We have discovered new glycosylated fatty acid amides, stellettosides, from a Stelletta sp. marine sponge. They were detected through LC-MS analysis of the extract combined with the cytotoxicity assay of the prefractionated sample. Their planar structures were determined by analyses of the NMR and tandem FABMS data. Stellettosides A1 and A2 (1 and 2) as well as stellettosides B1–B4 (3–6) were obtained

  我们已经发现了新的糖基化的脂肪酸酰胺，stellettosides，从Stelletta SP。海洋海绵。通过提取物的LC-MS分析和预分离样品的细胞毒性测定相结合，对它们进行了检测。通过分析NMR和串联FABMS数据确定了它们的平面结构。硬脂甙A1和A2（1和2）以及硬脂甙B1-B4（3 – 6）是不可分离的混合物。仔细分析每种混合物的NMR和串联FABMS数据，以及将串联FABMS数据与合成模型化合物的数据进行比较，使我们能够确定混合物中各成分的结构。手性衍生化后，通过LC-MS确定单糖单元的绝对构型。通过异亚丙基衍生物的1 H NMR数据确定脂肪酸链上邻位氧化次甲基的相对构型。（stellettosides B1-B4的混合物3 - 6）显示出适度的细胞毒性活性对HeLa细胞的IC 50 浓度为9μM，而硬脂甙A1和A2（1和2）的混合物在10μM的浓度下没有活性。
• Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells
  申请人：Allegretti Marcello

  公开号：US20050080067A1

  公开（公告）日：2005-04-14

  (R)-2-Arylpropionamide compounds of formula (I) are described. The process for their preparation and pharmaceutical preparations thereof are also described. The 2-Arylpropionamides of the invention are useful in the prevention and treatment of tissue damage due to the exacerbate recruitment of polymorphonuclear leukocytes (leukocytes PMN) and of monocytes at the inflammatory sites. In particular, the invention relates to the R enantiomers of omega-aminoalkylamides of 2-aryl propionic acids, of formula (I), for use in the inhibition of the chemotaxis of neutrophils and monocytes induced by the C5a fraction of the complement and by other chemotactic proteins whose biological activity is associated with activation of a 7-TD receptor. Selected compounds of formula (I) are dual inhibitors of both the C5a-induced chemotaxis of neutrophils and monocytes and the IL-8-induced chemotaxis of PMN leukocytes. The compounds of the invention are used in the treatment of psoriasis, ulcerative cholitis, glomerular nephritis, acute respiratory insufficiency, idiopathic fibrosis, rheumatoid arthritis and in the prevention and the treatment of injury caused by ischemia and reperfusion.

  本文描述了化合物公式(I)的(R)-2-Arylpropionamide化合物，以及它们的制备过程和制药制剂。发明的2-Arylpropionamides可用于预防和治疗由于炎症部位的多形核白细胞（白细胞PMN）和单核细胞的加重招募而导致的组织损伤。特别地，本发明涉及公式(I)的2-aryl丙酸的ω-氨基烷基酰胺的R对映体，用于抑制由补体的C5a分数和其他趋化蛋白引起的中性粒细胞和单核细胞趋化，并且这些趋化蛋白的生物活性与7-TD受体的激活有关。公式(I)的选定化合物是同时抑制C5a诱导的中性粒细胞和单核细胞趋化以及IL-8诱导的PMN白细胞趋化的双重抑制剂。本发明的化合物用于治疗牛皮癣、溃疡性结肠炎、肾小球肾炎、急性呼吸功能不全、特发性纤维化、类风湿性关节炎以及预防和治疗缺血再灌注引起的损伤。
• OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS
  申请人：ALLEGRETTI Marcello

  公开号：US20080045522A1

  公开（公告）日：2008-02-21

  (R)-2-Arylpropionamide compounds of formula (I) are described. The process for their preparation and pharmaceutical preparations thereof are also described. The 2-Arylpropionamides of the invention are useful in the prevention and treatment of tissue damage due to the exacerbate recruitment of polymorphonuclear leukocytes (leukocytes PMN) and of monocytes at the inflammatory sites. In particular, the invention relates to the R enantiomers of omega-aminoalkylamides of 2-aryl propionic acids, of formula (I), for use in the inhibition of the chemotaxis of neutrophils and monocytes induced by the C5a fraction of the complement and by other chemotactic proteins whose biological activity is associated with activation of a 7-TD receptor. Selected compounds of formula (I) are dual inhibitors of both the C5a-induced chemotaxis of neutrophils and monocytes and the IL-8-induced chemotaxis of PMN leukocytes. The compounds of the invention are used in the treatment of psoriasis, ulcerative cholitis, glomerular nephritis, acute respiratory insufficiency, idiopathic fibrosis, rheumatoid arthritis and in the prevention and the treatment of injury caused by ischemia and reperfusion.

  本文描述了公式(I)的(R)-2-芳基丙酰胺化合物，以及它们的制备过程和制药制剂。本发明中的2-芳基丙酰胺类化合物可用于预防和治疗由于在炎症部位诱导多形核白细胞（白细胞PMN）和单核细胞的加重招募而导致的组织损伤。特别是，本发明涉及公式(I)的ω-氨基烷基酰胺的R对映体，用于抑制由C5a补体分数和其他趋化蛋白诱导的中性粒细胞和单核细胞趋化，其生物活性与7-TD受体的激活有关。公式(I)的某些选择性化合物是同时抑制C5a诱导的中性粒细胞和单核细胞趋化以及IL-8诱导的PMN白细胞趋化的双重抑制剂。本发明中的化合物用于治疗牛皮癣、溃疡性结肠炎、肾小球肾炎、急性呼吸功能不全、特发性纤维化、类风湿关节炎以及预防和治疗缺血再灌注所致的损伤。
• Muscarinic receptor antagonists
  申请人：Aggen James

  公开号：US20090306134A1

  公开（公告）日：2009-12-10

  Disclosed are multibinding compounds which are muscarinic receptor antagonists. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of each other, a muscarinic receptor antagonist or an allosteric modulator provided that at least one of said ligand is a muscarinic receptor antagonist. The multibinding compounds of this invention are useful in the treatment and prevention of diseases such as chronic obstructive pulmonary disease, chronic bronchitis, irritable bowel syndrome, urinary incontinence, and the like.

  本发明涉及一种多结合化合物，其为肌动蛋白受体拮抗剂。该发明的多结合化合物包含2至10个配体共价连接到一个或多个连接体上。每个配体是独立的，可以是肌动蛋白受体拮抗剂或变构调节剂，但至少其中一个配体是肌动蛋白受体拮抗剂。本发明的多结合化合物在治疗和预防慢性阻塞性肺疾病、慢性支气管炎、肠易激综合征、尿失禁等疾病方面具有用途。
• "OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS"
  申请人：Dompé S.p.A.

  公开号：US20130079514A1

  公开（公告）日：2013-03-28

  (R)-2-Arylpropionamide compounds of formula (I), pharmaceutical preparations of the compounds and a process for making the compounds are described. The 2-Arylpropionamides of the invention are useful in the prevention and treatment of tissue damage due to the exacerbated recruitment of polymorphonuclear leukocytes and monocytes at inflammatory sites. In particular, the invention relates to the R enantiomers of omega-aminoalkylamides of 2-aryl propionic acids, of formula (I), for use as inhibitors of chemotaxis of neutrophils and monocytes induced by the C5a fraction of complement and by other chemotactic proteins whose biological activity is associated with activation of a 7-TD receptor. Selected compounds of formula (I) are dual inhibitors of both the C5a-induced chemotaxis of neutrophils and monocytes and the IL-8-induced chemotaxis of polymorphonuclear leukocytes.

  本文描述了式(I)的(R)-2-Arylpropionamide化合物、该化合物的制药制剂以及制备该化合物的方法。本发明中的2-Arylpropionamides可用于预防和治疗由于在炎症部位过度招募多形核白细胞和单核细胞而引起的组织损伤。特别地，本发明涉及公式(I)的omega-氨基烷基酰胺的R对映体，用作抑制与激活7-TD受体相关的C5a补体分数和其他趋化蛋白引起的中性粒细胞和单核细胞趋化的抑制剂。公式(I)的选定化合物是同时抑制C5a诱导的中性粒细胞和单核细胞趋化以及IL-8诱导的多形核白细胞趋化的双重抑制剂。